215 related articles for article (PubMed ID: 16891456)
1. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
[TBL] [Abstract][Full Text] [Related]
2. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
3. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target.
Yan C; Shieh B; Reigan P; Zhang Z; Colucci MA; Chilloux A; Newsome JJ; Siegel D; Chan D; Moody CJ; Ross D
Mol Pharmacol; 2009 Jul; 76(1):163-72. PubMed ID: 19364812
[TBL] [Abstract][Full Text] [Related]
4. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK.
González-Aragón D; Alcaín FJ; Ariza J; Jódar L; Barbarroja N; López-Pedrera C; Villalba JM
Chem Biol Interact; 2010 Jul; 186(2):174-83. PubMed ID: 20433816
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
Winski SL; Faig M; Bianchet MA; Siegel D; Swann E; Fung K; Duncan MW; Moody CJ; Amzel LM; Ross D
Biochemistry; 2001 Dec; 40(50):15135-42. PubMed ID: 11735396
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
Gustafson DL; Siegel D; Rastatter JC; Merz AL; Parpal JC; Kepa JK; Ross D; Long ME
J Pharmacol Exp Ther; 2003 Jun; 305(3):1079-86. PubMed ID: 12649308
[TBL] [Abstract][Full Text] [Related]
7. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
[TBL] [Abstract][Full Text] [Related]
8. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism.
Cullen JJ; Hinkhouse MM; Grady M; Gaut AW; Liu J; Zhang YP; Weydert CJ; Domann FE; Oberley LW
Cancer Res; 2003 Sep; 63(17):5513-20. PubMed ID: 14500388
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
Colucci MA; Reigan P; Siegel D; Chilloux A; Ross D; Moody CJ
J Med Chem; 2007 Nov; 50(23):5780-9. PubMed ID: 17944451
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H:quinone oxidoreductase 1-compromised human bone marrow endothelial cells exhibit decreased adhesion molecule expression and CD34+ hematopoietic cell adhesion.
Zhou H; Dehn D; Kepa JK; Siegel D; Scott DE; Tan W; Ross D
J Pharmacol Exp Ther; 2010 Jul; 334(1):260-8. PubMed ID: 20378716
[TBL] [Abstract][Full Text] [Related]
11. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
Siegel D; Gustafson DL; Dehn DL; Han JY; Boonchoong P; Berliner LJ; Ross D
Mol Pharmacol; 2004 May; 65(5):1238-47. PubMed ID: 15102952
[TBL] [Abstract][Full Text] [Related]
12. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
Siegel D; Shieh B; Yan C; Kepa JK; Ross D
J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
[TBL] [Abstract][Full Text] [Related]
13. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
14. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
15. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
Kolossov VL; Ponnuraj N; Beaudoin JN; Leslie MT; Kenis PJ; Gaskins HR
Biochem Biophys Res Commun; 2017 Jan; 483(1):680-686. PubMed ID: 27986568
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress.
Lewis A; Ough M; Li L; Hinkhouse MM; Ritchie JM; Spitz DR; Cullen JJ
Clin Cancer Res; 2004 Jul; 10(13):4550-8. PubMed ID: 15240547
[TBL] [Abstract][Full Text] [Related]
17. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger.
Zhu H; Jia Z; Mahaney JE; Ross D; Misra HP; Trush MA; Li Y
Cardiovasc Toxicol; 2007; 7(3):202-11. PubMed ID: 17901563
[TBL] [Abstract][Full Text] [Related]
18. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.
Nolan KA; Zhao H; Faulder PF; Frenkel AD; Timson DJ; Siegel D; Ross D; Burke TR; Stratford IJ; Bryce RA
J Med Chem; 2007 Dec; 50(25):6316-25. PubMed ID: 17999461
[TBL] [Abstract][Full Text] [Related]
19. Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen.
Moffit JS; Aleksunes LM; Kardas MJ; Slitt AL; Klaassen CD; Manautou JE
Toxicology; 2007 Feb; 230(2-3):197-206. PubMed ID: 17188792
[TBL] [Abstract][Full Text] [Related]
20. Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.
Park EJ; Min KJ; Choi KS; Kwon TK
Exp Cell Res; 2014 Apr; 323(1):144-154. PubMed ID: 24462458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
